Corpus ID: 27688939

Clinical trials with diglycoaldehyde (NSC-118994): review and reasons for withdrawal from clinical trial.

@article{Chiuten1981ClinicalTW,
  title={Clinical trials with diglycoaldehyde (NSC-118994): review and reasons for withdrawal from clinical trial.},
  author={D. Chiuten and G. Vosika and M. Shaw and M. Boiron and C. Gisselbrecht and M. Marty and G. Higgins and F. Muggia},
  journal={Anticancer research},
  year={1981},
  volume={1 2},
  pages={
          121-4
        }
}
All Phase II studies with diglycoaldehyde with leukemia and solid tumors have been reviewed. The dose schedules employed ranged from 1.5 to 2.0 g/m2/day for 3 to 5 days. The most common side effects have been gastrointestinal (nausea and vomiting), which occurred in 22% of the patients. Renal toxicity (rise in BUN, creatinine, and urinary proteins) was seem in 17% of the patients treated. Other infrequent toxicities include hypocalcemia (9%) and local complications such as phlebitis. Leukopenia… Expand
Inhibitory effect of adenosine dialdehyde on in situ murine neuroblastoma growth.
TLDR
The data suggest that steady state infusions of AD can significantly suppress murine neuroblastoma tumor growth with little systemic toxicity, in contrast to single daily injections of AD, which were ineffective and toxic to the tumor bearing host. Expand
Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data
TLDR
Examination of additional data for mRNA expression, sets of known molecular targets and mutational status against these same tumor cell lines to relate chemosensitivity more precisely to biochemical pathways finds that gene expression levels do not, in general, correlate with log(GI(50)) measurements, instead they reflect a generic toxic condition. Expand
Fanconi anemia-independent DNA inter-strand crosslink repair in eukaryotes.
TLDR
Current work on the transcription-coupled, base excision, acetaldehyde-induced, and SNM1A/RecQ4 ICL repair pathways are reviewed, highlighting unanswered questions in the field and enabling ICL-inducing agents to be more effectively used as chemotherapeutics. Expand